Alyeska Investment Group
FATE icon

Alyeska Investment Group’s Fate Therapeutics FATE Stock Holding History

Alyeska Investment Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-33,285
Closed -$1.14M – 510
2020
Q2 		$1.14M Buy
+33,285
New +$992K 0.02% 398
2018
Q1 		– Sell
-300,000
Closed -$1.83M – 465
2017
Q4 		$1.83M Buy
+300,000
New +$1.34M 0.01% 347
2016
Q1 		– Sell
-168,881
Closed -$569K – 409
2015
Q4 		$569K Sell
168,881
-10,505
-6% -$44.2K 0.01% 353
2015
Q3 		$956K Sell
179,386
-33,781
-16% -$231K 0.01% 392
2015
Q2 		$1.38M Buy
213,167
+130,604
+158% +$781K 0.02% 382
2015
Q1 		$404K Buy
82,563
+6,069
+8% +$30.1K 0.01% 475
2014
Q4 		$385K Buy
76,494
+25,012
+49% +$110K 0.01% 456
2014
Q3 		$263K Buy
51,482
+405
+0.8% +$2.34K 0.01% 366
2014
Q2 		$322K Buy
+51,077
New +$360K 0.01% 384

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Alyeska Investment Group's FATE Position: Q3 2020 in Review

Alyeska Investment Group sold out of Fate Therapeutics (FATE) in Q3 2020, closing a stake of 33,285 shares — an estimated $1.14M sold.

Alyeska Investment Group first reported a position in FATE in Q2 2014 and held it in 9 quarters. The position peaked at $1.83M in Q4 2017. 211 funds tracked by Wall St. Rank hold FATE as of Q3 2020.

  • Alyeska Investment Group reported no remaining Fate Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 33,285 Fate Therapeutics shares in Q3 2020, an estimated $1.14M.
  • Alyeska Investment Group first reported a position in Fate Therapeutics in Q2 2014 and held it in 9 quarters.
  • Alyeska Investment Group's Fate Therapeutics position peaked at $1.83M in Q4 2017.
  • 211 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2020.

Based on Alyeska Investment Group's 13F filing for Q3 2020, filed 16 Nov 2020.